NCT03199300 2025-12-11
InvestiCAT
University Medical Center Groningen
Active not recruiting
Clinical Trials
15 trialsNCT01771458 2025-11-24
SHIVA
Institut Curie
Phase 2 Completed
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT06031233 2025-05-21
MINUTE
Isala
Phase 4 Recruiting
NCT04551521 2025-01-08
CRAFT: The NCT-PMO-1602 Phase II Trial
German Cancer Research Center
Phase 2 Completed
NCT04309578 2024-02-28
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
Asan Medical Center
Phase 2 Unknown
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT02213289 2021-04-08
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
University of Chicago
Phase 2 Completed
NCT01295086 2020-11-02
Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer
Odense University Hospital
Phase NA Completed
NCT01396707 2020-01-07
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX
Asan Medical Center
Phase 2 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT03588533 2018-07-17
HERZUMA-GC
Dong-A University Hospital
Phase 2 Unknown
NCT01472029 2017-06-19
HerFLOT
AIO-Studien-gGmbH
Phase 2 Completed
NCT01235897 2014-04-17
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
University of California, San Francisco
Phase 1 Completed
NCT00637325 2008-03-17
TOP
Regione Lombardia
Phase 3 Unknown